1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Lyrica for Risk of Fulminant Hepatitis, Hepatic Dysfunction
August 25, 2014
- Eisai Sues FDA over Shortened Exclusivity Time for Belviq, Fycompa
August 22, 2014
- MHLW Plans to Build Clinical Trial/Clinical Research Network with Centralized Disease-Based Patient Registry: FY2015 Preliminary Budget Request
August 22, 2014
- Report of Changes to Package Inserts to Be Required Before Providing Revised Information to Healthcare Professionals Under New System
August 21, 2014
- Health Sciences Council to Include “Program to Promote Joint Drug Development by Govt and Private Sector” in FY2015 Budget Request
August 21, 2014
- Generic Use Promotion Best Possible Way for Reducing Social Welfare Expenses: LDP Kono
August 20, 2014
- MHLW Drug Evaluation Head Eyes Flexible Designation Criteria for New Fast-Track Review System
August 19, 2014
- Emergency Use of Favipiravir to Be Permitted if Domestic Outbreak of Ebola Occurs: Health Minister
August 19, 2014
- 148 Blopress Generics OKed, Competition with AGs Likely upon December Listing
August 15, 2014
- MHLW to Lift Ban on Subcontracting of Safety Management Tasks in November
August 15, 2014
- Health Ministry Notifies Prefectures of New Regulatory Service Fees
August 14, 2014
- First Meeting of PMDA’s Panel on Placebo-Controlled Studies Set in Early October
August 13, 2014
- PMDA Will Prosper by Promoting Review Work, Research, and Training Together: Chief Executive
August 13, 2014
- Health, Science Ministries Solicit Public Comments on New Clinical Research Ethics Guidelines
August 12, 2014
- Editor’s Pick: Five Healthcare News Headlines for July 28 - August 8
August 11, 2014
- PAFSC Second Committee Supports Approval of G-CSF Drug Pegfilgrastim
August 11, 2014
- Upcoming Act on Pharmaceuticals and Medical Devices to Require “Latest Information in Package Inserts”: PFSB
August 11, 2014
- MHLW Orders Revision of Package Insert for Remicade
August 8, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 3: Dr Yamamoto of SCJ
August 8, 2014
- Govt to Enhance Support to Boost Pharma Sector’s Competitiveness: Health Policy Bureau Head
August 7, 2014
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…